HHS Study Finds Medicare Part D Underutilizing Biosimilars
Millions Of Dollars In Potential Savings Have Been Lost
Research from the US HHS has found that millions of dollars could be saved by Medicare by increasing the biosimilar coverage of Part D plans.
You may also be interested in...
The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall
Blockbusters like Stelara, Eliquis, Prolia and Ibrance are poised to lose US exclusivity over the next five years; pressure is mounting for industry to replenish the portfolio with the next high-growth brands.
Medicare Part D Patients Paying More For Generics
The latest AAM-sponsored study from Avalere Health has found that, for the third year in the row, an increasing percentage of generic drugs are being placed on higher-cost non-generic tiers, even as the overall price of generic drugs decreases.
Two-Tier Specialty Drug Policy: Part D Plans Gain Formulary Flexibility But Impact May Be Limited
Use of preferred and non-preferred specialty formulary tiers will be allowed but preferred tiers are not necessarily limited to generics and biosimilars and coinsurance for non-preferred specialty drugs cannot exceed 33%.